Tirzepatide Peptide: Complete Research Guide (2026)

Tirzepatide is a dual GIP/GLP-1 receptor agonist studied for metabolic and weight regulation research. Here is everything researchers need to know.

May 13, 20269 min read

What is tirzepatide?

Tirzepatide is a synthetic 39-amino-acid peptide that uniquely activates two incretin receptors at once: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual agonism is what differentiates it from single-agonist peptides such as semaglutide or liraglutide.

Originally developed under the code LY3298176, tirzepatide has been the subject of the SURPASS and SURMOUNT clinical programs, which evaluated its impact on glycemic regulation and body-weight outcomes in adults.

Mechanism of action (research context)

GLP-1 receptor activation slows gastric emptying, enhances glucose-dependent insulin secretion, and signals satiety in the central nervous system. GIP receptor activation, long thought to be only mildly relevant to weight, appears in research data to amplify the GLP-1 effect when both receptors are co-activated by a single molecule.

In published trial data, tirzepatide produced larger reductions in HbA1c and body weight than GLP-1-only comparators at matched doses — a finding that has driven significant scientific interest in dual and triple incretin agonists.

Reconstitution & handling

Tirzepatide ships as a lyophilized white powder under vacuum.
Reconstitute with bacteriostatic water (BAC water). A common research ratio is 2 mL BAC water per 10 mg vial, yielding 5 mg/mL.
Add the diluent slowly down the side of the vial — do not shake. Swirl gently until fully dissolved.
Store reconstituted solution refrigerated at 2–8 °C and use within 30 days.
Lyophilized powder is stable at –20 °C for long-term storage; protect from light.

Dosing studied in clinical trials

Across the SURPASS and SURMOUNT programs, tirzepatide was studied at 2.5 mg, 5 mg, 10 mg, and 15 mg administered subcutaneously once weekly. Trials used a stepwise titration starting at 2.5 mg for four weeks, then escalating in 2.5 mg increments every four weeks until the target dose was reached.

This information describes published trial protocols only and is not dosing guidance — research use only.

Tirzepatide vs semaglutide vs retatrutide

Semaglutide is a GLP-1-only agonist. Tirzepatide adds GIP. Retatrutide goes further by adding glucagon receptor activation, making it a triple agonist. Each step up in receptor coverage has correlated with larger metabolic effects in trial data, but also with a different side-effect profile that researchers continue to characterize.

Quality control checklist

HPLC purity ≥ 99% on the certificate of analysis
Mass spectrometry confirming molecular weight (~4,813.5 Da)
Endotoxin and sterility testing for lyophilized vials
Lot number and date of synthesis printed on the vial label

Frequently asked questions

How is tirzepatide peptide stored before reconstitution?

Lyophilized tirzepatide should be kept at –20 °C for long-term storage and protected from light and moisture. Short-term storage at 2–8 °C is acceptable for several weeks.

What is the typical reconstitution ratio used in research?

A 10 mg vial is commonly reconstituted with 2 mL of bacteriostatic water, yielding a 5 mg/mL solution. The ratio is chosen by the researcher based on the dosing protocol.

How does tirzepatide differ from semaglutide?

Semaglutide activates GLP-1 receptors only, while tirzepatide activates both GIP and GLP-1 receptors. Trial data shows tirzepatide produced larger HbA1c and body-weight reductions than semaglutide at matched doses.